Skip to content

CHANGE -it is About Life

CHANGE.A Randomized Clinical Trial of Health Promoting Programme Versus Standard Treatment for Patients With Schizophrenia

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01585493
Enrollment
428
Registered
2012-04-26
Start date
2012-12-31
Completion date
2016-06-30
Last updated
2016-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia, Metabolic Syndrome

Keywords

Lifestyle, Smoking, Dietary, Exercise

Brief summary

Schizophrenia is a life shortening disease, not only because of suicide but also because of increased mortality from natural causes. Recently, a large register-based study, involving complete national data from Denmark, Sweden and Finland, showed that life expectancy for schizophrenia is 20 years shorter for men and 15 years shorter for women, compared to the general population, and that mortality from medical conditions and diseases are responsible for a large proportion of the reduced life expectancy. Patients with schizophrenia had a twofold to fivefold increased risk of death by coronary heart disease, respiratory diseases, lung cancer and metabolic conditions. Unhealthy life style and undetected and untreated physical disorders play an important role in this excess mortality.Results from the Danish National Indicator Project for Schizophrenia showed that a much higher proportion of patients with schizophrenia compared to the general population have measures of waist circumference, body mass index, blood pressure, blood lipids and blood glucoses above the recommended upper values. In the randomized clinical trial CHANGE, the investigators will evaluate the effect of two different interventions both aiming to reduce risk for death from medical diseases. We will compare 1) treatment as usual with 2) affiliation to a care coordinator who has the duty to connect the patient to general practice and primary care and 3) affiliation to a staff member from the CHANGE team who should facilitate life style changes and contact with general practice. The objective is to identify interventions that can reduce the risk of early death in patients with schizophrenia.

Interventions

OTHERTreatment as usual

Treatment as usual. Patients will be affiliated with local out-patient clinics in secondary mental health services and they will have access to their own general practitioner. No formalized extra effort will be made to ensure treatment of physical disorders.Patients will be affiliated with local out-patient clinics in secondary

Treatment as usual plus a care coordinator (with a caseload of 25 patients) who will facilitate contact to primary care in order to ensure treatment of physical health problems,

BEHAVIORALCHANGE

Treatment as usual plus affiliation to a staffmember (caseload 10) from a CHANGE team who will provide individualized, adjusted implementation of widely recognized interventions, such as smoking cessation programmes, motivational interviewing, psychoeducation plus patient involvement in monitoring health statusA multidisciplinary CHANGE team will be established. Team members will be health professionals with experience in smoking cessation programmes or exercise programmes for mentally ill, and experts with competence in dietary issues. CHANGE treatment involve lifestyle coaching, education about diet and physical activity,16 networking and smoking cessation programs. The team members will act as lifestyle coaches for ten patients at a time, map lifestyle and explore and elicit patients' motivation for change.

Sponsors

University of Copenhagen
CollaboratorOTHER
Mental Health Services in the Capital Region, Denmark
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Affiliated to outpatients services at Mental Health Centre, Copenhagen or Århus University Hospital * Diagnose ICD-10:F2 spectrum * Waist circumference \> 88 cm for women or \>102 cm for men

Exclusion criteria

* Not willing to participate

Design outcomes

Primary

MeasureTime frameDescription
Copenhagen Risk Score12 monthsThe primary outcome is change in 10 years risk of cardiovascular disease from baseline at 12 months.

Secondary

MeasureTime frameDescription
Body mass index12 monthsChange in body mass index at 12 months
Blood pressure12 monthsChange in systolic and diastolic blood pressure at 12 months
Cholesterol12 monthsChange in total Cholesterol, LDL, HDL, and triglycerides and 12 months
Aerobic fitness12 monthsIndirectly estimated maximal oxygen uptake
Waist circumference12 monthsMeasured between crista iliaca and the lowest rib
Forced expiratory volume12 months
Resting heart rate12 months
HbA1c12 months
Physical activity12 monthsChange in minutes of MVPA a week
Smoking12 monthsNumber of daily smokers in each group at 12 months
Sedentary lifestyle12Self reported hours of sedentary behavior

Other

MeasureTime frame
Quality of life12 months
Dietary pattern12 months
Self rated health12 months
High sensitive CRP12 months
Triglycerides12 months
Global assessment functioning (GAF)12 months
Positive and negative symptoms12 months
Cognition12 months

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 4, 2026